

Pierluigi Porcu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6250585/publications.pdf>

Version: 2024-02-01

190
papers

6,862
citations

70961

41
h-index

69108

77
g-index

195
all docs

195
docs citations

195
times ranked

7758
citing authors

#	ARTICLE	IF	CITATIONS
1	Identification and Targeting of the Developmental Blockade in Extranodal Natural Killer/T-cell Lymphoma. <i>Blood Cancer Discovery</i> , 2022, 3, 154-169.	2.6	8
2	The Two-Step Allogeneic Stem Cell Transplantation Approach Results in Rapid Engraftment and Excellent Outcomes in Patients with Lymphoid Malignancies. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 159.e1-159.e5.	0.6	2
3	Cytokines in the Pathogenesis of Large Granular Lymphocytic Leukemia. <i>Frontiers in Oncology</i> , 2022, 12, 849917.	1.3	8
4	Dermal fibroblasts promote cancer cell proliferation and exhibit fibronectin overexpression in early mycosis fungoides. <i>Journal of Dermatological Science</i> , 2022, 106, 53-60.	1.0	2
5	Incidence, Treatment, and Survival of Patients With T-Cell Lymphoma, T-Cell Large Granular Leukemia, and Concomitant Plasma Cell Dyscrasias. <i>Frontiers in Oncology</i> , 2022, 12, 858426.	1.3	0
6	Clinical outcomes in T-cell large granular lymphocytic leukaemia: prognostic factors and treatment response. <i>British Journal of Haematology</i> , 2021, 192, 484-493.	1.2	6
7	Quality of Life Effect of the Anti-CCR4 Monoclonal Antibody Mogamulizumab Versus Vorinostat in Patients With Cutaneous T-cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 97-105.	0.2	18
8	Phase I/II study of bendamustine in combination with ofatumumab, carboplatin, etoposide (BOCE) for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2021, 62, 590-597.	0.6	2
9	New insights on treatment utilization and outcomes in early-stage mycosis fungoides. <i>British Journal of Dermatology</i> , 2021, 184, 594-595.	1.4	0
10	Clinical characteristics and outcomes of black patients with mycosis fungoides and S�azary syndrome: a subgroup analysis of the phase III MAVORIC trial. <i>Leukemia and Lymphoma</i> , 2021, 62, 1877-1883.	0.6	10
11	The rise of a new "elegant teacher". <i>Blood</i> , 2021, 138, 205-206.	0.6	1
12	Treating Early-Stage DLBCL on the FLYER: What Lesson for Radiation Therapy?. <i>Frontiers in Oncology</i> , 2021, 11, 686223.	1.3	1
13	Autologous EBV-specific T cell treatment results in sustained responses in patients with advanced extranodal NK/T lymphoma: results of a multicenter study. <i>Annals of Hematology</i> , 2021, 100, 2529-2539.	0.8	12
14	Design and Implementation of a Multipurpose Information System for Hematopoietic Stem-Cell Transplantation on the Basis of the Biomedical Research Integrated Domain Group Model. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 1076-1084.	1.0	0
15	Survival Analysis of Patients with T-Cell Lymphoma or T-Cell Large Granular Leukemia and Concomitant Plasma Cell Dyscrasias. <i>Blood</i> , 2021, 138, 2449-2449.	0.6	0
16	Nanatinostat (Nstat) and Valganciclovir (VGCV) in Relapsed/Refractory (R/R) Epstein-Barr Virus-Positive (EBV +) Lymphomas: Final Results from the Phase 1b/2 VT3996-201 Study. <i>Blood</i> , 2021, 138, 623-623.	0.6	17
17	Molecular Characterization Using Oncoscan Chromosome Microarray in an International Cohort of 51 Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). <i>Blood</i> , 2021, 138, 3497-3497.	0.6	0
18	Implementation of an Outpatient HD-MTX Initiative. <i>Frontiers in Oncology</i> , 2021, 11, 773397.	1.3	1

#	ARTICLE	IF	CITATIONS
19	Durable Response to Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, and Prednisone (BV-CHP) in a Patient with CD30-Positive PTCL Arising as a Post-Transplant Lymphoproliferative Disorder (PTLD). <i>Current Oncology</i> , 2021, 28, 5067-5072.	0.9	5
20	A case series of primary cutaneous B-cell lymphomas with atypical presentations: diagnostic and therapeutic Challenges. <i>Haematologica</i> , 2021, , .	1.7	0
21	Applied Genomics and Public Health <i>Cancer Genomics.</i> , 2020, , 53-72.		0
22	Gemcitabine and bendamustine is a safe and effective salvage regimen for patients with recurrent/refractory Hodgkin lymphoma: Results of a phase 1/2 study. <i>Cancer</i> , 2020, 126, 1235-1242.	2.0	8
23	Low Nonrelapse Mortality after HLA-Matched Related 2-Step Hematopoietic Stem Cell Transplantation Using Cyclophosphamide for Graft-versus-Host Disease Prophylaxis and the Potential Impact of Non-Cyclophosphamide-Exposed T Cells on Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1861-1867.	2.0	2
24	Management of Patients With Hematologic Malignancies During the COVID-19 Pandemic: Practical Considerations and Lessons to Be Learned. <i>Frontiers in Oncology</i> , 2020, 10, 1439.	1.3	26
25	Clinical Features Predictive of Survival in Patients With Vitreoretinal Lymphoma: Analysis of 70 Patients at a Single Ocular Oncology Center. <i>Asia-Pacific Journal of Ophthalmology</i> , 2020, 9, 110-116.	1.3	15
26	Skindex-29 scores indicate poor quality of life in early stage mycosis fungoides. <i>Journal of Dermatological Science</i> , 2020, 98, 98-101.	1.0	3
27	Topical imiquimod monotherapy for indolent primary cutaneous Bâ€cell lymphomas: a singleâ€institution experience. <i>British Journal of Dermatology</i> , 2020, 183, 386-387.	1.4	4
28	Improved outcomes for extranodal natural killer T-cell lymphoma. <i>Lancet Haematology</i> ,the, 2020, 7, e272-e273.	2.2	2
29	Romidepsin Plus Liposomal Doxorubicin Is Safe and Effective in Patients with Relapsed or Refractory T-Cell Lymphoma: Results of a Phase I Dose-Escalation Study. <i>Clinical Cancer Research</i> , 2020, 26, 1000-1008.	3.2	26
30	A prospective cohort study of condensed low-dose total skin electron beam therapy for mycosis fungoides: Reduction of disease burden and improvement in quality of life. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 78-85.	0.6	14
31	COVID-19 in Patients with Hematologic Malignancies: A Single-Center Experience. <i>Blood</i> , 2020, 136, 36-37.	0.6	1
32	Oral Nanatinostat (Nstat) and Valganciclovir (VGCV) in Patients with Recurrent Epstein-Barr Virus (EBV)-Positive Lymphomas: Initial Phase 2 Results. <i>Blood</i> , 2020, 136, 7-8.	0.6	1
33	Successful Treatment of Mature T-Cell Lymphoma with Allogeneic Stem Cell Transplantation: The Largest Multicenter Retrospective Analysis. <i>Blood</i> , 2020, 136, 35-36.	0.6	7
34	Vaccination Response after Autologous Stem Cell Transplantation. <i>Blood</i> , 2020, 136, 25-26.	0.6	1
35	Recent Advances in Cutaneous T-cell Lymphoma. <i>Surgical Pathology Clinics</i> , 2019, 12, 783-803.	0.7	12
36	TREATMENT PATTERNS, CLINICAL OUTCOMES, AND BIOMARKER EVALUATION IN CLASSICAL HODGKIN LYMPHOMA: A PROSPECTIVE OBSERVATIONAL STUDY IN US ONCOLOGY PRACTICES. <i>Hematological Oncology</i> , 2019, 37, 486-487.	0.8	0

#	ARTICLE	IF	CITATIONS
37	Preclinical Targeting of MicroRNA-214 in Cutaneous T-Cell Lymphoma. <i>Journal of Investigative Dermatology</i> , 2019, 139, 1966-1974.e3.	0.3	22
38	A PHASE 1B/2 STUDY OF ORAL NANATINOSTAT (N) AND VALGANCICLOVIR (VG) IN SUBJECTS WITH EPSTEIN-BARR VIRUS (EBV)-ASSOCIATED LYMPHOMAS. <i>Hematological Oncology</i> , 2019, 37, 335-337.	0.8	0
39	Autologous Stem Cell Transplantation for Multiple Myeloma: Growth Factor Matters. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e293-e297.	2.0	6
40	Extreme Peripheral Blood Plasmacytosis Mimicking Plasma Cell Leukemia as a Presenting Feature of Angioimmunoblastic T-Cell Lymphoma (AITL). <i>Frontiers in Oncology</i> , 2019, 9, 509.	1.3	12
41	Mogamulizumab versus investigator choice in relapsed/refractory adult T-cell leukemia/lymphoma: all four one or none for all?. <i>Haematologica</i> , 2019, 104, 864-867.	1.7	2
42	Brentuximab vedotin in the treatment of CD30+ PTCL. <i>Blood</i> , 2019, 134, 2339-2345.	0.6	20
43	TELLOMAK: T-CELL LYMPHOMA ANTI-KIR3DL2 THERAPY: AN OPEN LABEL, MULTI-COHORT, MULTI-CENTER, INTERNATIONAL PHASE II STUDY EVALUATING THE EFFICACY AND SAFETY OF IPH4102 ALONE OR IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH ADVANCED T-CELL LYMPHOMA. <i>Hematological Oncology</i> , 2019, 37, 72-73.	0.8	0
44	PHASE I STUDY OF ROMIDEPSIN AND LIPOSOMAL DOXORUBICIN IN RELAPSED OR REFRACTORY T-CELL LYMPHOMA. <i>Hematological Oncology</i> , 2019, 37, 335-335.	0.8	0
45	Peripheral T-Cell Lymphoma, not Otherwise Specified (PTCL-NOS). <i>Cancer Treatment and Research</i> , 2019, 176, 83-98.	0.2	25
46	Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. <i>Lancet, The</i> , 2019, 393, 229-240.	6.3	517
47	Valchlor maintenance therapy for patients with mycosis fungoides who received low dose total skin electron beam treatment. <i>Chinese Clinical Oncology</i> , 2019, 8, 13-13.	0.4	18
48	Allogeneic hematopoietic stem cell transplantation in advanced stage mycosis fungoides and SÅ©zary syndrome: a concise review. <i>Chinese Clinical Oncology</i> , 2019, 8, 12-12.	0.4	17
49	The spectrum of CD30+ T cell lymphoproliferative disorders in the skin. <i>Chinese Clinical Oncology</i> , 2019, 8, 3-3.	0.4	11
50	Immune evasion and current immunotherapy strategies in mycosis fungoides (MF) and SÅ©zary syndrome (SS). <i>Chinese Clinical Oncology</i> , 2019, 8, 11-11.	0.4	18
51	Systemic therapy of cutaneous T-cell lymphoma (CTCL). <i>Chinese Clinical Oncology</i> , 2019, 8, 20-20.	0.4	33
52	Emerging insights on the biology and treatment of cutaneous T-cell lymphoma. <i>Chinese Clinical Oncology</i> , 2019, 8, 1-1.	0.4	2
53	Reversible DNA Hypermethylation of the Interleukin-15 (IL-15) Promoter Induces IL-15 Expression, Drives the Pathogenesis of T-Cell Large Granular Lymphocytic Leukemia and Provides a Potential Therapeutic Approach Using 5-Azacidine. <i>Blood</i> , 2019, 134, 3776-3776.	0.6	2
54	Results of a Phase I/II Study of Bendamustine in Combination with Ofatumumab, Carboplatin and Etoposide (BOCE) for Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas. <i>Blood</i> , 2019, 134, 5318-5318.	0.6	0

#	ARTICLE	IF	CITATIONS
55	A Prospective Cohort of Black Patients with Mycosis Fungoides and SÅ©zary Syndrome: Subset Analysis of the Mavoric Trial. <i>Blood</i> , 2019, 134, 4766-4766.	0.6	0
56	Complete and Durable Responses in Primary Central Nervous System Posttransplant Lymphoproliferative Disorder with Zidovudine, Ganciclovir, Rituximab, and Dexamethasone. <i>Clinical Cancer Research</i> , 2018, 24, 3273-3281.	3.2	20
57	Activity of the PI3K-Î³ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma. <i>Blood</i> , 2018, 131, 888-898.	0.6	224
58	The Use of Central Pathology Review With Digital Slide Scanning in Advanced-stage Mycosis Fungoides and SÅ©zary Syndrome. <i>American Journal of Surgical Pathology</i> , 2018, 42, 726-734.	2.1	17
59	Diminished microRNA-29b level is associated with BRD4-mediated activation of oncogenes in cutaneous T-cell lymphoma. <i>Blood</i> , 2018, 131, 771-781.	0.6	42
60	Duvelisib, a novel oral dual inhibitor of PI3K-Î³, is clinically active in advanced hematologic malignancies. <i>Blood</i> , 2018, 131, 877-887.	0.6	199
61	Targeting STAT5 or STAT5-Regulated Pathways Suppresses Leukemogenesis of Ph+ Acute Lymphoblastic Leukemia. <i>Cancer Research</i> , 2018, 78, 5793-5807.	0.4	17
62	Highly cytotoxic natural killer cells are associated with poor prognosis in patients with cutaneous T-cell lymphoma. <i>Blood Advances</i> , 2018, 2, 1818-1827.	2.5	11
63	Duvelisib, an oral dual PI3K-Î³ inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 study. <i>American Journal of Hematology</i> , 2018, 93, 1318-1326.	2.0	45
64	Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 1192-1204.	5.1	398
65	Targeting the Bcl-2 Family in B Cell Lymphoma. <i>Frontiers in Oncology</i> , 2018, 8, 636.	1.3	106
66	2 Step Myeloablative Haploidentical Transplant (HI MA HSCT) in Intermediate and High-Risk Patients-Changing the Timing of the 2 Step Approach. <i>Blood</i> , 2018, 132, 4661-4661.	0.6	0
67	A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas. <i>Leukemia and Lymphoma</i> , 2017, 58, 2310-2318.	0.6	43
68	A positive randomised trial in cutaneous T-cell lymphoma. <i>Lancet</i> , The, 2017, 390, 533-534.	6.3	0
69	NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2017. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 293-311.	2.3	55
70	Systemic therapy for cutaneous T-cell lymphoma: who, when, what, and why?. <i>Expert Review of Hematology</i> , 2017, 10, 111-121.	1.0	13
71	Frequency and clinical correlates of elevated plasma Epstein-Barr virus DNA at diagnosis in peripheral T-cell lymphomas. <i>International Journal of Cancer</i> , 2017, 140, 1899-1906.	2.3	15
72	Expanding and expounding the genomic map of CTCL. <i>Blood</i> , 2017, 130, 1389-1390.	0.6	1

#	ARTICLE	IF	CITATIONS
73	Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium. <i>Annals of Oncology</i> , 2017, 28, 2517-2525.	0.6	98
74	Phase I Study of IPH4102, Anti-KIR3DL2 Mab, in Relapsed/Refractory Cutaneous T-Cell Lymphomas (CTCL): Dose-escalation Safety, Biomarker and Clinical Activity Results. <i>Hematological Oncology</i> , 2017, 35, 48-49.	0.8	8
75	MicroRNA-181 contributes to downregulation of SAMHD1 expression in CD4+ T-cells derived from SÅzary syndrome patients. <i>Leukemia Research</i> , 2017, 52, 58-66.	0.4	21
76	Overview of the Use of Murine Models in Leukemia and Lymphoma Research. <i>Frontiers in Oncology</i> , 2017, 7, 22.	1.3	71
77	Editorial: Murine Models of Leukemia and Lymphoma. <i>Frontiers in Oncology</i> , 2017, 7, 309.	1.3	0
78	Phase 1 trial evaluating MRG-106, a synthetic inhibitor of microRNA-155, in patients with cutaneous t-cell lymphoma (CTCL).. <i>Journal of Clinical Oncology</i> , 2017, 35, 7564-7564.	0.8	17
79	Emerging insights on the pathogenesis and treatment of extranodal NK/T cell lymphomas (ENKTL). <i>Discovery Medicine</i> , 2017, 23, 189-199.	0.5	14
80	NKp80 Defines a Critical Step during Human Natural Killer Cell Development. <i>Cell Reports</i> , 2016, 16, 379-391.	2.9	100
81	NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 1067-1079.	2.3	107
82	SÅzary Syndrome: Clinical and Biological Aspects. <i>Current Hematologic Malignancy Reports</i> , 2016, 11, 468-479.	1.2	17
83	Cutaneous mantle cell lymphoma: a clinicopathologic review of 10 cases. <i>Journal of Cutaneous Pathology</i> , 2016, 43, 1112-1120.	0.7	13
84	Increased Levels of Plasma Epstein Barr Virus DNA Identify a Poor-Risk Subset of Patients With Advanced Stage Cutaneous T-Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, S181-S190.e4.	0.2	7
85	Mechanism, Consequences, and Therapeutic Targeting of Abnormal IL15 Signaling in Cutaneous T-cell Lymphoma. <i>Cancer Discovery</i> , 2016, 6, 986-1005.	7.7	79
86	Extranodal NK/T Cell Lymphoma, Nasal Type (ENKTL-NT): An Update on Epidemiology, Clinical Presentation, and Natural History in North American and European Cases. <i>Current Hematologic Malignancy Reports</i> , 2016, 11, 514-527.	1.2	149
87	Pembrolizumab for Treatment of Relapsed/Refractory Mycosis Fungoides and Sezary Syndrome: Clinical Efficacy in a Citn Multicenter Phase 2 Study. <i>Blood</i> , 2016, 128, 181-181.	0.6	56
88	First-in-Human, Multicenter Phase I Study of IPH4102, First-in-Class Humanized Anti-KIR3DL2 Monoclonal Antibody, in Relapsed/Refractory Cutaneous T-Cell Lymphomas: Preliminary Safety, Exploratory and Clinical Activity Results. <i>Blood</i> , 2016, 128, 1826-1826.	0.6	6
89	Preliminary Results of a Phase 1 Trial Evaluating MRG-106, a Synthetic microRNA Antagonist (LNA) Tj ETQq1 1 0.784314 rgBT /Overlook	0.6	44
90	Management and Outcomes of Atrial Fibrillation in Patients Receiving Ibrutinib for Hematologic Malignancies at a Single Center. <i>Blood</i> , 2016, 128, 2040-2040.	0.6	2

#	ARTICLE	IF	CITATIONS
91	Safety and Preliminary Efficacy Results of a Phase I First-in-Human Study of the Novel Notch-1 Targeting Antibody Brontictuzumab (OMP-52M51) Administered Intravenously to Patients with Hematologic Malignancies. <i>Blood</i> , 2016, 128, 5108-5108.	0.6	23
92	A phase 2 randomized study of SHAPE Gel (SHP-141) in patients with early-stage cutaneous T-cell lymphoma: Interim results.. <i>Journal of Clinical Oncology</i> , 2016, 34, 7562-7562.	0.8	7
93	First-in-human, open label, multicenter phase I of IPH4102, first-in-class humanized anti-KIR3DL2 monoclonal antibody, in relapsed/refractory cutaneous T-cell lymphomas.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS2591-TPS2591.	0.8	0
94	Autologous Transplantation As Consolidation for High Risk Aggressive T-Cell Non-Hodgkin's Lymphoma: A SWOG S9704 Intergroup Trial Subgroup Analysis. <i>Blood</i> , 2016, 128, 4651-4651.	0.6	0
95	Extranodal Marginal Zone Lymphomaâ€“like Presentations of Angioimmunoblastic T-Cell Lymphoma. <i>American Journal of Dermatopathology</i> , 2015, 37, 604-613.	0.3	20
96	Human Leukocyte Antigen Type and Posttransplant Lymphoproliferative Disorder. <i>Transplantation</i> , 2015, 99, 1220-1225.	0.5	22
97	The Role of an Integrated Multidisciplinary Clinic in the Management of Patients with Cutaneous Lymphoma. <i>Frontiers in Oncology</i> , 2015, 5, 136.	1.3	24
98	Targeting Interleukin-2-inducible T-cell Kinase (ITK) and Resting Lymphocyte Kinase (RLK) Using a Novel Covalent Inhibitor PRN694. <i>Journal of Biological Chemistry</i> , 2015, 290, 5960-5978.	1.6	36
99	Cutaneous T-Cell Lymphoma. , 2015, , 363-377.		0
100	Treating Cutaneous T-Cell Lymphoma with Highly Irregular Surfaces with Photon Irradiation Using Rice as Tissue Compensator. <i>Frontiers in Oncology</i> , 2015, 5, 49.	1.3	3
101	Complex Karyotype Is Associated With Aggressive Disease and Shortened Progression-Free Survival in Patients With Newly Diagnosed Mantle Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 278-285.e1.	0.2	19
102	Promoter-Specific Hypomethylation Is Associated with Overexpression of PLS3 , GATA6 , and TWIST1 in the Sezary Syndrome. <i>Journal of Investigative Dermatology</i> , 2015, 135, 2084-2092.	0.3	32
103	The Epstein-Barr Virus (EBV) in T Cell and NK Cell Lymphomas: Time for a Reassessment. <i>Current Hematologic Malignancy Reports</i> , 2015, 10, 456-467.	1.2	60
104	Genomic analyses reveal recurrent mutations in epigenetic modifiers and the JAKâ€“STAT pathway in SÅžary syndrome. <i>Nature Communications</i> , 2015, 6, 8470.	5.8	177
105	Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and SÅžary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model. <i>Journal of Clinical Oncology</i> , 2015, 33, 3766-3773.	0.8	328
106	Primary Cutaneous Bâ€“Cell Lymphoma: Management and Patterns of Recurrence at the Multimodality Cutaneous Lymphoma Clinic of The Ohio State University. <i>Oncologist</i> , 2015, 20, 1161-1166.	1.9	21
107	Primary cutaneous B-cell lymphoma: management and patterns of recurrence at the Multimodality Cutaneous Lymphoma Clinic of the Ohio State University. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, S62.	0.2	0
108	Elevated plasma Epstein-Barr virus DNA at diagnosis predicts a poor prognosis in peripheral T-cell lymphomas. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, S67.	0.2	2

#	ARTICLE	IF	CITATIONS
109	A Single Institution Experience with EPOCH in Peripheral T-cell Lymphomas (PTCL). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, S68.	0.2	1
110	Serum chemokines and cytokines in CLL patients treated with duvelisib, a PI3K- $\hat{\gamma}$, $\hat{\beta}$ inhibitor.. <i>Journal of Clinical Oncology</i> , 2015, 33, 7072-7072.	0.8	1
111	Blastic Plasmacytoid Dendritic Cell Neoplasm: A Single-Center Experience Documenting Frequent CNS Involvement. <i>Blood</i> , 2015, 126, 5602-5602.	0.6	0
112	Genome-Wide Mapping Reveals BRD4 in Regulation of Tumor-Driver Genes in Cutaneous T-Cell Lymphoma. <i>Blood</i> , 2015, 126, 589-589.	0.6	2
113	Flavopiridol can be safely administered using a pharmacologically derived schedule and demonstrates activity in relapsed and refractory non-Hodgkin's lymphoma. <i>American Journal of Hematology</i> , 2014, 89, 19-24.	2.0	26
114	Downregulation of SAMHD1 Expression Correlates with Promoter DNA Methylation in S \hat{A} zary Syndrome Patients. <i>Journal of Investigative Dermatology</i> , 2014, 134, 562-565.	0.3	50
115	Non-Hodgkin's Lymphomas, Version 4.2014. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 1282-1303.	2.3	144
116	Targeting Interleukin-2-Inducible T-Cell Kinase (ITK) and Resting Lymphocyte Kinase (RLK) Using a Novel Covalent Inhibitor PRN694. <i>Blood</i> , 2014, 124, 272-272.	0.6	1
117	The Oral Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) Demonstrates Broad and Durable Clinical Activity in Relapsed / Refractory Non Hodgkin's Lymphoma (NHL). <i>Blood</i> , 2014, 124, 396-396.	0.6	27
118	A Phase I Study of Ibrutinib and Lenalidomide in Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma. <i>Blood</i> , 2014, 124, 4476-4476.	0.6	7
119	Epstein-Barr Virus Kinase-Targeted Therapy for Primary Central Nervous System Post-Transplant Lymphoproliferative Disorder. <i>Blood</i> , 2014, 124, 1750-1750.	0.6	0
120	Monoclonal Antibodies (mAb) in the Therapy of T-Cell Lymphomas. , 2013, , 243-261.		0
121	Impaired Proteasome Function Activates GATA3 in T Cells and Upregulates CTLA-4: Relevance for S \hat{A} zary Syndrome. <i>Journal of Investigative Dermatology</i> , 2013, 133, 249-257.	0.3	41
122	Promoter Methylation Regulates SAMHD1 Gene Expression in Human CD4+ T Cells. <i>Journal of Biological Chemistry</i> , 2013, 288, 9284-9292.	1.6	67
123	Periocular cutaneous anaplastic large cell lymphoma clearance with brentuximab vedotin. <i>Journal of Clinical and Aesthetic Dermatology</i> , 2013, 6, 29-31.	0.1	20
124	Aberrant Overexpression of IL-15 Initiates Large Granular Lymphocyte Leukemia through Chromosomal Instability and DNA Hypermethylation. <i>Cancer Cell</i> , 2012, 22, 645-655.	7.7	150
125	Post Autologous Transplant Vorinostat (SAHA) in High Risk Lymphoma: Phase 1 Study of Vorinostat Maintenance. <i>Blood</i> , 2012, 120, 2004-2004.	0.6	2
126	Phase I Study of AR-42 in Relapsed Multiple Myeloma and Lymphoma.. <i>Blood</i> , 2012, 120, 2955-2955.	0.6	4

#	ARTICLE	IF	CITATIONS
127	SÅ©zary syndrome: Immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC). Journal of the American Academy of Dermatology, 2011, 64, 352-404.	0.6	154
128	Early CTCL diagnosis, a (miR)age no more?. Blood, 2011, 118, 5717-5718.	0.6	8
129	Evolving Insights in the Pathogenesis and Therapy of Cutaneous Tâ€cell lymphoma (Mycosis Fungoides) Tj ETQq1 1,0,784314,pgBT /C	1.2	127
130	Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma. Cancer, 2011, 117, 2442-2451.	2.0	52
131	Successful Treatment of Primary Central Nervous System Post-Transplant Lymphoproliferative Disorder (PCNS-PTLD) with Zidovudine (AZT), Ganciclovir (GCV), Rituximab and Dexamethasone: A Single-Institution Case Series. Blood, 2011, 118, 3067-3067.	0.6	1
132	The Prognostic Value of FDG PET/CT Prior to Autologous Stem Cell Transplant in Mantle Cell Lymphoma. Blood, 2011, 118, 3113-3113.	0.6	0
133	Risk Factors for Post-Transplant Lymphoproliferative Disorder in Solid Organ Transplant Recipients. Blood, 2011, 118, 4465-4465.	0.6	0
134	Results of A Phase I Study of Milatuzumab, a Humanized Anti-CD74 Antibody, and Veltuzumab, a Humanized Anti-CD20 Antibody, In Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma,. Blood, 2011, 118, 3707-3707.	0.6	0
135	T-plastin (PLS3) gene expression differentiates SÅ©zary syndrome from mycosis fungoides and inflammatory skin diseases and can serve as a biomarker to monitor disease progression. British Journal of Dermatology, 2010, 162, 463-466.	1.4	31
136	Flavopiridol, Fludarabine, and Rituximab in Mantle Cell Lymphoma and Indolent B-Cell Lymphoproliferative Disorders. Journal of Clinical Oncology, 2010, 28, 418-423.	0.8	84
137	The State of Cutaneous Lymphomas: A Call to Action. Clinical Lymphoma, Myeloma and Leukemia, 2010, 10, S55-S58.	0.2	2
138	A Look at the National Comprehensive Cancer Network Guidelines for Cutaneous Lymphomas. Clinical Lymphoma, Myeloma and Leukemia, 2010, 10, S109-S111.	0.2	2
139	Cutaneous CD4+ CD56+ hematologic malignancies. Journal of the American Academy of Dermatology, 2010, 63, 292-308.	0.6	30
140	New Targets of Therapy in T-Cell Lymphomas. Current Drug Targets, 2010, 11, 482-493.	1.0	8
141	Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin lymphoma. Leukemia and Lymphoma, 2009, 50, 349-356.	0.6	12
142	Combination bortezomib and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphoma. MAbs, 2009, 1, 31-40.	2.6	33
143	A phase I/II dose escalation study of apolizumab (Hu1D10) using a stepped-up dosing schedule in patients with chronic lymphocytic leukemia and acute leukemia. Leukemia and Lymphoma, 2009, 50, 1958-1963.	0.6	32
144	Allogeneic Stem Cell Transplantation for Patients with Relapsed Chemorefractory Aggressive Non-Hodgkin Lymphomas. Biology of Blood and Marrow Transplantation, 2009, 15, 547-553.	2.0	39

#	ARTICLE	IF	CITATIONS
145	We Should Have a Dream: Unlocking the Workings of the Genome in Cutaneous T-Cell Lymphomas. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, 409-411.	1.4	5
146	Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2009, 50, 1232-1234.	0.6	0
147	Reversal of neurological deficit after chemotherapy in BCL-6-positive neurolymphomatosis. <i>Journal of Neurosurgery</i> , 2009, 111, 247-251.	0.9	10
148	Subcutaneous alemtuzumab for SÅ©zary Syndrome in the very elderly. <i>Leukemia Research</i> , 2008, 32, 1299-1303.	0.4	40
149	Atypical lymphocytic lobular panniculitis: a clonal subcutaneous Tâ€cell dyscrasia. <i>Journal of Cutaneous Pathology</i> , 2008, 35, 947-954.	0.7	43
150	Highâ€dose therapy and autologous stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large Bâ€cell lymphoma. <i>European Journal of Haematology</i> , 2008, 81, 425-431.	1.1	35
151	Feasibility of allogeneic hematopoietic stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2008, 49, 1893-1898.	0.6	10
152	Flavopiridol, Fludarabine and Rituximab (FFR): An Active Regimen in Indolent B-Cell Lymphoproliferative Disorders and Mantle Cell Lymphoma.. <i>Blood</i> , 2008, 112, 1571-1571.	0.6	1
153	A Phase II Trial of Induction Plus Maintenance Rituximab and Bortezomib in Patients with Relapsed/Refractory Mantle Cell (MCL) and Follicular (FL) Non-Hodgkinâ€™s Lymphoma. <i>Blood</i> , 2008, 112, 3053-3053.	0.6	1
154	Assessment of Rabbit Antithymocyte Globulin (rATG) Dose-Intensity in Patients with Hematological Malignancies Undergoing Allogeneic Stem Cell Transplantation (ASCT) Following Reduced Intensity Conditioning (RIC) with Fludarabine, Busulfan and rATG (FBA). <i>Blood</i> , 2008, 112, 4405-4405.	0.6	0
155	Allogeneic Stem Cell Transplantation for Patients with Chemo-Refractory or Progressive Aggressive Non-Hodgkinâ€™s Lymphomas.. <i>Blood</i> , 2008, 112, 3265-3265.	0.6	0
156	Therapeutic Apheresis in Hyperleukocytosis and Hyperviscosity Syndrome. <i>Seminars in Thrombosis and Hemostasis</i> , 2007, 33, 350-354.	1.5	86
157	Results of a phase II study of 506U78 in cutaneous T-cell lymphoma and peripheral T-cell lymphoma: CALGB 59901. <i>Leukemia and Lymphoma</i> , 2007, 48, 97-103.	0.6	39
158	CD4+CD56+haematodermic tumour (plasmacytoid dendritic cell neoplasm). <i>British Journal of Haematology</i> , 2007, 140, 071107173701001-???	1.2	2
159	Primary Cutaneous CD30+ Large Cell B-Cell Lymphoma. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2006, 14, 7-11.	0.6	32
160	Fine-needle aspiration biopsy of non-Hodgkin lymphoma for use in expression microarray analysis. <i>Cancer</i> , 2006, 108, 311-318.	2.0	12
161	CD8+ Lymphomatoid Papulosis and Its Differential Diagnosis. <i>American Journal of Clinical Pathology</i> , 2006, 125, 490-501.	0.4	54
162	Excessive Neurotoxicity in a Phase II Trial of Combined Bortezomib and Rituximab in Patients with Relapsed/Refractory Mantle Cell (MCL) and Follicular (FL) Non-Hodgkinâ€™s Lymphoma.. <i>Blood</i> , 2006, 108, 2768-2768.	0.6	0

#	ARTICLE	IF	CITATIONS
163	Epstein-Barr virus- and human herpesvirus 8-associated primary cutaneous plasmablastic lymphoma in the setting of renal transplantation. <i>Journal of Cutaneous Pathology</i> , 2005, 32, 35-39.	0.7	83
164	The absence of CD20 messenger RNA in recurrent cutaneous B-cell lymphoma following rituximab therapy. <i>Journal of Cutaneous Pathology</i> , 2005, 32, 616-621.	0.7	28
165	Epstein-Barr virus-associated B-cell lymphoma in the setting of iatrogenic immune dysregulation presenting initially in the skin. <i>Journal of Cutaneous Pathology</i> , 2005, 32, 474-483.	0.7	51
166	Flavopiridol, Fludarabine and Rituximab Is a Highly Active Regimen in Indolent B-Cell Lymphoproliferative Disorders Including Mantle Cell Lymphoma.. <i>Blood</i> , 2005, 106, 944-944.	0.6	5
167	Bexarotene-Induced T-Cell Immunomodulation and Response in CTCL.. <i>Blood</i> , 2004, 104, 744-744.	0.6	9
168	Conversion of antibody-resistant cancer patients to antibody-sensitive: Investigation of Fc receptor polymorphisms and response to IL-2 and rituximab treatment in rituximab-refractory NHL patients. <i>Journal of Clinical Oncology</i> , 2004, 22, 2534-2534.	0.8	1
169	Automated kappa and lambda light chain mRNA expression for the assessment of B-cell clonality in cutaneous B-cell infiltrates: its utility and diagnostic application. <i>Journal of Cutaneous Pathology</i> , 2003, 30, 504-511.	0.7	31
170	Polypoid endobronchial Hodgkin lymphoma with an initial response to photodynamic therapy. <i>Annals of Thoracic Surgery</i> , 2003, 76, 940-942.	0.7	3
171	Recent developments in the biology and therapy of T-cell and natural killer cell lymphomas. <i>Current Opinion in Oncology</i> , 2003, 15, 353-362.	1.1	14
172	AIDS-associated malignancies. <i>Cancer Chemotherapy and Biological Response Modifiers</i> , 2003, 21, 717-746.	0.5	4
173	Experimental treatment of Epstein-Barr virus-associated primary central nervous system lymphoma. <i>Cancer Research</i> , 2003, 63, 965-71.	0.4	70
174	Successful treatment of posttransplantation lymphoproliferative disorder (PTLD) following renal allografting is associated with sustained CD8+ T-cell restoration. <i>Blood</i> , 2002, 100, 2341-2348.	0.6	54
175	Leukocytoreduction for Acute Leukemia. <i>Therapeutic Apheresis and Dialysis</i> , 2002, 6, 15-23.	0.6	126
176	In Situ Determination of B-Cell Heavy Chain and Kappa/Lambda Light Chain Expression Patterns: Methodology and Clinical Utility. <i>Diagnostic Molecular Pathology</i> , 2001, 10, 171-178.	2.1	6
177	In Situ Determination of T-cell Receptor Beta Expression Patterns. <i>Journal of Histochemistry and Cytochemistry</i> , 2001, 49, 139-145.	1.3	10
178	Results of Treatment After Relapse From High-Dose Chemotherapy in Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2000, 18, 1181-1186.	0.8	85
179	Hyperleukocytic Leukemias and Leukostasis: A Review of Pathophysiology, Clinical Presentation and Management. <i>Leukemia and Lymphoma</i> , 2000, 39, 1-18.	0.6	311
180	Clinical and Basic Science Studies of Human Umbilical Cord Blood. , 2000, , .		0

#	ARTICLE	IF	CITATIONS
181	Acquired immunodeficiency syndrome-related lymphomas: future directions. <i>Seminars in Oncology</i> , 2000, 27, 454-62.	0.8	13
182	Sacrococcygeal teratoma in adults. , 1999, 86, 1198-1202.		71
183	Thrombotic thrombocytopenic purpura and simvastatin. <i>Lancet, The</i> , 1998, 352, 1284-1285.	6.3	54
184	Alloantigen-induced unresponsiveness in cord blood T lymphocytes is associated with defective activation of Ras. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1998, 95, 4538-4543.	3.3	45
185	Therapeutic leukapheresis in hyperleucocytic leukaemias: lack of correlation between degree of cyto-reduction and early mortality rate. <i>British Journal of Haematology</i> , 1997, 98, 433-436.	1.2	135
186	Cell Cycle Control by the IGF-1 Receptor and Its Ligands. <i>Advances in Experimental Medicine and Biology</i> , 1994, 343, 105-112.	0.8	23
187	The growth-stimulatory effect of simian virus 40 T antigen requires the interaction of insulinlike growth factor 1 with its receptor.. <i>Molecular and Cellular Biology</i> , 1992, 12, 5069-5077.	1.1	109
188	The insulin-like growth factor 1 receptor is required for the proliferation of hemopoietic cells. <i>Oncogene</i> , 1992, 7, 2243-8.	2.6	69
189	Inhibition of cellular proliferation by peptide analogues of insulin-like growth factor 1. <i>Cancer Research</i> , 1992, 52, 6447-51.	0.4	153
190	Lymphokine-activated killer (LAK) cells inhibit the clonogenic growth of human leukemic stem cells. <i>European Journal of Haematology</i> , 1989, 42, 425-430.	1.1	23